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Abstract
Background: HIV patients are known to be at increased risk of lung cancer but the risk factors behind this are
unclear.
Methods: We estimated the cumulative incidence and relative risk of lung cancer in 1) a population of all Danish
HIV patients identified from the Danish HIV Cohort Study (n = 5,053) and a cohort of population controls matched
on age and gender (n = 50,530) (study period; 1995 - 2009) and 2) their parents (study period; 1969 - 2009).
Mortality and relative risk of death after a diagnosis of lung cancer was estimated in both populations.
Results: 29 (0.6%) HIV patients vs. 183 (0.4%) population controls were diagnosed with lung cancer in the
observation period. HIV patients had an increased risk of lung cancer (adjusted incidence rate ratio (IRR); 2.38 (95%
CI; 1.61 - 3.53)). The IRR was considerably increased in HIV patients who were smokers or former smokers (adjusted
IRR; 4.06 (95% CI; 2.66 - 6.21)), male HIV patients with heterosexual route of infection (adjusted IRR; 4.19 (2.20 -
7.96)) and HIV patients with immunosuppression (adjusted IRR; 3.25 (2.01 - 5.24)). Both fathers and mothers of HIV
patients had an increased risk of lung cancer (adjusted IRR for fathers; 1.31 (95% CI: 1.09 - 1.58), adjusted IRR for
mothers 1.35 (95% CI: 1.07 - 1.70)). Mortality after lung cancer diagnose was increased in HIV patients (adjusted
mortality rate ratio 2.33 (95%CI; 1.51 - 3.61), but not in the parents. All HIV patients diagnosed with lung cancer
were smokers or former smokers.
Conclusion: The risk was especially increased in HIV patients who were smokers or former smokers, heterosexually
infected men or immunosuppressed. HIV appears to be a marker of behavioural or family related risk factors that
affect the incidence of lung cancer in HIV patients.
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Background
After the introduction of highly active antiretroviral
therapy (HAART) HIV has changed from a fatal disease
to a chronic condition and well treated HIV patients
now have an overall life expectancy close to that of
non-HIV infected individuals [1]. Due to immunological
recovery, there has been a remarkable decline in AIDS
defining cancers whereas the increased risk of certain
non-AIDS defining cancers, including lung cancer has
persisted in the HIV population [2-6].
Lung cancer is primarily related to tobacco use and
t h er o l eo fH I Vi n f e c t i o ni nt h ed e v e l o p m e n to fl u n g
cancer is uncertain [7]. Several studies have shown that
both immunosuppressed patients after allograft organ
transplantation and HIV patients are at higher risk of
lung cancer [8]. Therefore immunodeficiency and
chronic inflammation are proposed to be major risk fac-
tors, besides smoking, involved in the lung cancer
pathogenesis. Whereas the role of HIV infection in lung
cancer development is questionable, most studies show
a decreased survival in HIV patients with lung cancer
[9-12]. We hypothesized that family related risk factors
may be part of the increased risk of lung cancer and
mortality and that HIV is a marker for the increased
risk independently of the pathogenicity of HIV. We
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the risk of lung cancer and survival among Danish HIV
patients, their parents and a cohort of population
controls.
Methods
In the first part of the study we estimate the incidence
of lung cancer in 1) HIV patients compared to popula-
tion controls matched on age and gender and 2) in the
parents of the HIV patients compared to the parents of
the population controls. In the second part of the study
we estimate the mortality of individuals diagnosed with
lung cancer in 1) HIV patients compared to population
controls matched on age and gender and 2) the parents
of the HIV patients compared to the parents of the
population controls.
Setting
Denmark had a population of 5.5 million as of 31
December 2008, with an estimated HIV prevalence of
approximately 0.09% in the adult population. Patients
with HIV infection are treated in the country’se i g h t
specialized medical centres, where they are seen on an
outpatient basis at intended intervals of 12 weeks. As
HAART is available only at these eight centres almost
no HIV patients are treated elsewhere. Antiretroviral
treatment is provided free of charge to all HIV-infected
residents of Denmark.
Data sources
We used the unique 10-digit civil registration number
assigned to all individuals in Denmark at birth or upon
immigration to link the data sources described below
[13].
The Danish HIV Cohort study (DHCS) is a popula-
tion-based prospective nationwide cohort study of all
HIV patients 16 years or older at diagnosis and who are
treated at Danish HIV centres after 1 January 1995 [14].
The HIV patients are consecutively enrolled, and multi-
ple registrations are avoided through the use of the
unique civil registration number. December 31, 2009 the
cohort included 5481 Danish residents. Data are
updated yearly and includes demographics, smoking sta-
tus, date of HIV infection, AIDS defining events, date
and cause of death and antiretroviral treatment. CD4
+
cell counts and HIV-RNA measurements are extracted
electronically from laboratory data files. Data on smok-
ing are not adequate in the database. Patients who were
registered at least once as consuming tobacco in any
quantity were considered smokers or former smokers.
We calculated the distribution of smokers or former
smokers among Danish HIV infected.
The Danish Civil Registration System (DCRS) was
established in 1968 and stores information of vital
status, residency as well as immigration and emigration
on all Danish residents [13]. Since 1 January 1969 the
registry also included identification of parents still alive
at this date.
The Danish Cancer Register is a population-based reg-
ister and contains information on incident cancers diag-
nosed in Danish Citizens since 1943. Details about
registration can be found elsewhere [15]. In 1969 - 2003
cancers were coded according to International Classifi-
cation of Disease version 7 (ICD-7) and International
Classification of Diseases for Oncology 1 (ICD-O-1)
with supplement from ICD-O-2 in 1990 - 2003. Since
2004 cancers have been coded according to ICD-O-3
and ICD-10 and data from the period 1978 - 2003 have
been converted to ICD-O-3 and ICD-10. We do not
have data on cancer staging or treatment from the Dan-
ish Cancer Register.
Data on smoking are not available in the Danish
national registries.
Study populations
HIV and population control Study populations
In the first part of the study, we included all HIV
patients from the Danish HIV Cohort Study without a
diagnosis of cancer prior to index date, see Figure 1.
The index date was defined as 1 January 1995, the date
of the HIV diagnosis or date of immigration, which ever
came last. For each of the HIV patients we identified 10
age- and gender matched population control subjects
from the DCRS who were alive and living in Denmark
at index date of the corresponding HIV patient (refereed
to also as the index date of the respective population
control) and not diagnosed with a cancer prior to index
date.
Parent study populations
In the parent study population we included all mothers
and fathers of the HIV patients and population controls
included who 1) gave birth to a index patient or popula-
tion control after 1 January 1952, 2) were alive and liv-
ing in Denmark after 1 January 1969 and 3) who were
not diagnosed with cancer prior to the parent index
date, see Figure 1. The parent index date was defined as
1 January 1969, date of birth of the included HIV
patient/population control or date of registration in
DCRS, whichever came last. In case a parent was the
father or mother of both an HIV patient and a popula-
tion control, they were included in both parent
populations.
Outcome
In the first study outcome was time to first diagnosis
of lung cancer. We identified all primary lung cancers
in the populations using cancer diagnoses as defined
by NORDCAN [16]; see cancer definitions in
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Page 2 of 10Additional file 1. Lung cancer was defined according to
NORDCAN: 1620, 1621, 1628 in ICD-7 and C34 in
ICD-10. In order to investigate if there was any differ-
ence in the histopathological distribution of lung can-
cer perhaps due to immunodeficiency we grouped the
lung cancers into five groups following the 1999 WHO
classification [17] categorized by the following ICD-O-
3 codes; 1) squamous cell carcinoma (M80503 - 80763,
M80833), 2) small cell carcinoma (M80403 - 80453), 3)
adenocarcinoma (M82303 -823133, M82503 - 82603,
M84803 - 84903, M85503 - 85603, M85703 - 85723,
M81403, M82113, M83233) 4) large cell carcinoma
(M80123 -80313, M83103) and 5) other carcinomas
(M85603, M82403, M82493, M84303, M82003,
M85623, M80463) and unclassified malignant cells
(M80013, M80103, M82463, M99903, M99993).
In the second part of the study outcome was time to
death.
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excluded:                                   
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count once)             
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parent were not alive or 
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DK after index date:  
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diagnosis before index 
date:  
5,053 fathers of 
 HIV patients 
5,053 mothers of  
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(20.7%) 
1,558 
(30.8%) 
15  
(0.3%) 
2  
(<0.1%) 
3  
(<0.1%) 
1,047 
(20.7%) 
1,387 
(27.4%) 
17 
(0.3%) 
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population controls: 
Excluded because 
offspring were born 
before 1 January 1952:  
Not traceable and 
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population control 
siblings (only count once):    
Excluded because the 
parent were not alive or 
did not have residency in 
DK after index date:  
Excluded due to cancer 
diagnosis before index 
date:  
10,470  
(79.3%) 
7,589 
(15.0) 
446 
(0.9%) 
55   
(0.1%) 
41    
(0.1%) 
10,470 
(79.3%) 
6,822 
(13.5%) 
437 
(0.9%) 
13 
(<0.1%) 
83   
(1.6%) 
50,530 fathers of  
population controls 
50,530 mothers of  
population controls 
Figure 1 Summary of the study design.
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Differences in characteristics between groups were eval-
uated by the c
2 test and Kruskal-Wallis Test when
appropriate.
We estimated the probability of lung cancer and the
relative risk of lung cancer in all study populations.
Observation time was calculated from the respective
index date to date of diagnosis of lung cancer or other
cancers, death, 1 January 2009, emigration or lost to fol-
low-up, whichever came first. We used cumulative inci-
dence function to illustrate time to first lung cancer,
recognizing death and diagnoses of other cancers as a
competing risk [18]. Incidence rate ratios (IRR) and 95%
confidence intervals for lung cancer as estimates of rela-
tive risks were calculated using Cox proportional-
hazards regression. In the comparison of HIV patients
and their matched population controls we used Cox
regression analyses stratified according to the initial
match criteria (age and gender).
In order to identify risk factors for lung cancer in the
HIV population, we calculated incidence rate ratios
(IRRs) stratified by gender, race (native vs. immigrant),
age at index date (≤ 50 years vs. > 50 years), diagnosis
of HIV before 1 January 1995, smoking (smoker or for-
mer smoker in any quantity vs. never smoked), route of
infection (men who have sex with men (MSM) vs. het-
erosexually infected men vs. heterosexually infected
women vs. injection drug user (IDU)), immunodefi-
ciency at index date (AIDS defining event or CD4 cell
count < 350 cells/μL vs. no AIDS defining event and
CD4 cell count ≥ 350 cells/μL). All results were adjusted
for age (continuous variable) and gender. Baseline CD4
cell count was defined as the measurement closest to
i n d e xd a t e+ / -o n ey e a r .A l s o ,w ei n c l u d e df i r s td a t e
with a CD4 count below 350/μLo rd a t eo ff i r s tA I D S
defining event as a time dependent variable.
IRRs for parent populations were adjusted for age at
parent index date (continuous variable) as well as year
of birth of the parent divided into the following decades:
- 1920, 1920-1930, 1930-1940, 1940-1950, 1950 - later.
A robustness analysis was performed where we calcu-
lated IRRs for lung cancer including only parents of
HIV patients and population controls born in Denmark.
In a sub analysis, we calculated IRR for the following
four types of lung cancers: Squamous cell carcinoma,
small cell carcinoma, adenocarcinoma and large cell
carcinoma.
We computed person-years at risk of dying from lung
cancer from date of the diagnosis to date of death, 1
January 2009, emigration or lost to follow up whichever
came first. We used Kaplan-Meier analysis to construct
survival curves and Cox regression analyses were used
to estimate mortality rate ratios (MRR). In the popula-
tion consisting of HIV patients and population controls
all results were adjusted for age at lung cancer diagnosis
(continuous variable) and gender. In the parent popula-
tion all results were adjusted for age at lung cancer
diagnosis (continuous variable) as well as year of birth
of the parent divided into the following decades: - 1920,
1920-1930, 1930-1940, 1940-1950, 1950 - later. The
study was approved by the Danish Data Protection
Agency. SPSS statistical software, Version 15.0 (Norusis;
SPSS Inc., Chicago, Illinois, USA) and R software, ver-
sion 2.8.1, was used for data analysis.
Results
In the first part of the study, we identified a total of
5,168 Danish HIV patients of which 115 were excluded
due to cancer diagnosed prior to index date, leaving
5,053 HIV patients and 50,530 age and gender matched
population controls in the study with a total of 37,622
and 470,322 person-years of follow-up, respectively
(figure 1). 1,165 (23.1%) died during follow-up, 17
(0.3%) were lost to follow-up and 173 (3.4%) emigrated.
85.8% of the HIV patients were male, 71.6% were native
Danes and 45.3% were MSMs. More patient characteris-
tics are described in table 1. 71.1% of the HIV study
population were smokers or former smokers in any
quantity and females and immigrant were less likely to
smoke whereas almost all IDUs smoked or used to
smoke (Additional file 2).
A total of 333 (6.6%) HIV patients and 1328 (2.6%)
population controls were diagnosed with a cancer in the
observation period of whom 29 (0.6%) and 183 (0.4%),
respectively, were diagnosed with lung cancer. Median
age at time of lung cancer was not significantly different
in the two cohorts. Their characteristics are listed in
table 1. All HIV patients with lung cancer were smokers.
20 (69.0%) of the HIV patients were treated with
HAART before diagnosed with lung cancer. Nadir CD4
cell count in the HIV patients diagnosed with lung can-
cer was 110 cells/μL (IQR; 45 cells/μL - 230 cells/μL)
and median CD4 cell count at time of cancer diagnosis
was 299 cells/μL (IQR; 130 cells/μL - 521 cells/μL). 17
(85.0%) of those in HAART were virally suppressed at
time of lung cancer diagnose.
As seen in figure 2, the HIV infected population had a
higher 10-year probability for lung cancer compared to
the control population. The incidence of lung cancer was
higher in HIV patients than in population controls
(adjusted IRR 2.38 (95% CI; 1.61 - 3.53)). The IRRs for
lung cancer remained high in most stratified analyses
except for female HIV patients. No events of lung cancer
were diagnosed among HIV patients who never smoked
(table 2). The highest risk of lung cancer were seen in
H I Vp a t i e n t sw h ow e r es m o k e r so rf o r m e rs m o k e r s
(adjusted IRR; 4.06 (95% CI; 2.66 - 6.21), male patients
with heterosexual route of HIV infection (adjusted IRR;
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Page 4 of 104.19 (95% CI; 2.20 - 7.96)) and HIV patients with prior
AIDS defining events or low baseline CD4 cell count
(adjusted IRR; 3.25 (95% CI; 2.01 - 5.24)).
In the time period after first date with a CD4 cell
count below 350 cells/μL or an AIDS defining event the
adjusted RR for lung cancer was 1.48 (95% CI; 0.63 -
3.47)) compared to HIV patients with intact or resti-
tuted immune system.
We identified a total of 2,428 fathers of HIV infected
individuals vs. 31,929 fathers of population controls and
2,586 mothers of HIV patients and 32,705 mothers of
population controls (figure 1). Age at paternal index
date and median follow-up time did not differ between
the parent populations (table 3). The 30-year probability
of lung cancer was higher for both fathers and mothers
of HIV patients (figure 3). The adjusted relative risk for
lung cancer for fathers and mothers of HIV patients was
1.31 (95% CI: 1.09 - 1.58) and 1.35 (95% CI: 1.07 - 1.70),
respectively. After stratification of the children’s route of
HIV infection, the relative risk remained high in all
groups particularly for parents of IDUs (adjusted IRR
for HIV fathers; 1.63 (95% CI: 1.02 - 2.58), adjusted IRR
for HIV mothers; 2.01 (95% CI: 1.21 - 3.36)) (table 4).
Sub-analyses
In a sub analysis including only squamous cell carci-
noma, small cell carcinoma, adenocarcinoma and large
cell carcinoma, 19 (0.4%) and 134 (0.3%) lung cancers
where diagnosed in the HIV patients and population
controls, respectively. The adjusted IRR was 2.11 (95%
CI: 1.30 - 3.42). In the parent population, 85 (3.4%) vs.
965 (2.9%) lung cancers were diagnosed in the fathers
and 60 (2.2%) vs. 597 (1.8%) in the mothers. The IRRs
were increased in both parents of HIV patients (HIV
Table 1 Characteristics of HIV patients and population controls with lung cancer
HIV patients
N = 5053,
HIV patients with
lung cancer
N = 29,
Population
controls
with lung cancer
N = 183,
P value*
N (%) N (%) N (%)
Male gender 3827 (75.7) 27 (93.1) 156 (85.2) 0.253
Age at time of index date, median (IQR), years 36.6 (30.4 - 44.3) 49.9 (42.7 - 59.7) 50.7 (45.1 - 59.5) 0.554
Age at time of cancer diagnosis, median (IQR), years - 57.0 (48.8 - 63.2) 58.9 (52.2 - 67.5) 0.192
Native Danes 3619 (71.6) 24 (82.8) 179 (97.8) > 0.001
Older than 50 years at index date 695 (13.8) 14 (58.3) 98 (53.6) 0.129
Diagnosed with HIV before 1 January 1995 1968 (38.9) 18 (62.1)
Smoker or former smoker in any quantity 2600 (71.1) 29 (100)
Route of HIV infection
Men who have sex with men 2287 (45.3) 12 (41.4)
Heterosexually infected men 934 (18.5) 12 (41.4)
Heterosexually infected women 930 (18.4) 2 (6.9)
Injection drug user 553 (10.9) 3 (10.3)
Other 349 (6.9) 0 (0.0)
Baseline CD4 < 350 cells/μL or AIDS defining event at index date 2655 (52.5) 20 (69.0)
Baseline CD4 cell count, cells/μL, median (IQR) 279 (104 - 480) 230 (86 - 403)
Histological classification of lung cancer HIV patients with
lung cancer
N=2 9
Population
controls
with lung cancer
N = 183
P value
Squamous cell carcinoma 8 (27.6) 36 (19.7)
Small cell carcinoma 4 (13.8) 31 (16.9)
Adenocarcinoma 7 (24.1) 55 (30.1)
Large cell carcinoma 0 (0) 12 (6.5)
Other and unclassified 10 (34.5)** 49 (26.8)***
P value for difference in distribution of HPV site, potential HPV site
and potentially unrelated HPV site
0.457
*P value for differences in characteristics between HIV patients and population controls with lung cancer
**3 carcinoma without other specifications (M80103), 3 Non-Large cell carcinomas (M80463), 2 adenosquamos carcinomas (M85603), 1 no microscopically
confirmed lung cancer (M99903) and 1 malignant histology unknown (M99993).
***2 neoplasm malignant (M80003), 3 malignant tumor cells (M80013), 3 carcinoma without other specifications (M80103), 22 Non-Large cell carcinomas
(M80463), 3 carcinoid tumor, malignant (M82403), 1 neuroendocrine carcinoma (M82463), 1 adenosquamous carcinomas (M85603), 12 not microscopically
confirmed lung cancer (M99903) and 2 malignant histology unknown (M99993).
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Page 5 of 10fathers adjusted; 1.17 (95% CI: 0.93 -1.76), HIV mothers
adjusted; 1.32 (95% CI: 1.01 -1.72)). Also in a robustness
analysis including only parents of HIV patients and
population controls born in Denmark, the relative risks
of lung cancer were increased (HIV fathers adjusted;
1.39 (95% CI: 1.15 -1.68), HIV mothers adjusted; 1.35
(95% CI: 1.06 -1.72)).
Mortality
25 HIV patients and 149 population controls with lung
cancer died during follow-up. Median survival time for
the HIV infected population was approximately two
months and seven months for the population controls
(figure 4). Adjusted MRR for the HIV patients with lung
cancer was 2.33 (95%CI; 1.51 - 3.51).
Survival in the parent populations did not differ
between parents of HIV patients and population con-
t r o l s( H I Vf a t h e r sa d j u s t e dM R R ;0 . 9 7( 9 5 % C I ;0 . 8 0-
1.18), HIV mothers adjusted; 0.96 (95%CI; 0.75 - 1.23).
Discussion and Conclusion
We found a more than twofold increased risk of lung
cancer in HIV patients compared with the background
population. The risk was especially increased in HIV
patients who were smokers or former smokers, hetero-
sexually infected men or immunosuppressed. Both
fathers and mothers of HIV patients had an increased
risk of lung cancer compared to the parents of the
non-HIV infected population controls. All HIV
patients diagnosed with lung cancer were smokers or
f o r m e rs m o k e r sa n dH I Va p p e a r e dt ob eam a r k e ro f
Figure 2 Cumulative incidence function for lung cancer among
HIV patients and population controls.
Table 2 Risk factors for lung cancer for HIV patients and population controls
Lung cancer (HIV/population
controls), N
Unadjusted IRR (95% CI) Adjusted IRR* (95% CI)
All 29/183 2.08 (1.41 - 3.08) 2.38 (1.61 - 3.53)
Stratification
Male gender* 27/156 2.33 (1.55 - 3.50) 2.66 (1.77 - 4.01)
Female gender 2/27 0.91 (0.22 - 3.82) **
Native 24/179 2.13 (2.39 - 3.27) 2.56 (1.47 - 3.46)
Immigrant 5/4 6.38 (1.71 - 23.86) **
Younger than or 50 years at index date 18/104 2.33 (1.35 - 4.04) 2.34 (1.35 - 4.06)
Older than 50 years at index date * 14/98 2.07 (1.18 - 3.63) 2.08 (1.19 - 3.65)
HIV diagnosed before 1995 18/112 2.34 (1.42 - 3.85) 2.60 (1.58 - 4.28)
HIV diagnosed after 1995 at index date 11/71 1.75 (0.93 - 3.31) 2.13 (1.12 - 4.03)
Smoker or former smoker in any quantity 29/81 3.79 (2.48 - 5.97) 4.06 (2.66 - 6.21)
Never smoked 0/35 ** **
Route of HIV infection
Men who have sex with men (MSM) 12/99 1.60 (0.88 - 2.91) 1.82 (0.99 - 3.12)
Heterosexually infected men 12/44 3.40 (1.80 - 6.45) 4.19 (2.20 - 7.96)
Heterosexually infected women 2/18 1.26 (0.30 - 5.44) **
Injection drug user (IDU) 3/13 1.95 (1.28 - 2.94) **
Baseline CD4 < 350 cells/μL or AIDS defining event at
index date
20/111 2.70 (1.68 - 4.35) 3.25 (2.01 - 5.24)
Baseline CD4 ≥ 350 cells/μL and no AIDS defining event
at index date
6/40 1.68 (0.71 - 3.96) 1.71 (0.72 - 4.03)
* All adjusted for gender and age, except the stratification on male which is only adjusted for age and age > 50 which is only adjusted for gender.
** Too few events for analysis.
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incidence of lung cancer independently of immunosup-
pression. Also the risk of death was more than twofold
increased in the HIV infected population with lung
cancer compared to the background population. The
increased risk of death in patients with lung cancer
appears to be related to the HIV infection since par-
ents of HIV infected with lung cancer did not have an
increased mortality.
To our knowledge this is the first nationwide study
comparing the incidence of lung cancer in HIV patients
with that of a matched control population. A major
strength of the study is the quality and coverage of the
Danish registries with access to valid data on family
members and the population-based design with long
and nearly complete follow-up.
We did not estimate the risk of lung cancer and death
according to the implementation of HAART. However,
the development of lung cancer presumably takes sev-
eral years and it is therefore difficult to estimate the
impact of risk factors that vary over time. Our registry
data did not allow direct adjustment for potential effects
of confounders like smoking. Therefore we chose to
include the parent population in order to demonstrate a
family related risk associated with lung cancer as an
indirect measure of risk behaviour. Our cohort had a
size that allowed us to detect the risk of rare outcomes
such as lung cancer. The small number of cases caused
some imprecision of our estimates and did not allow us
to perform complex multivariate analyses. Our study is
based on data extracted from registries and misclassifi-
cation cannot be ruled out. Still, calculations performed
on specific histologically confirmed lung cancer diag-
noses confirmed the increased risk in HIV patients. We
were not able to include data on lung cancer staging in
the mortality analysis which could confound our results.
Finally, a limitation of the study is the difference in the
proportion of traceable parents among HIV patients and
population controls due to a larger proportion of immi-
grants among the HIV patients. However, a robustness
analysis including only parents of HIV patients and
population controls born in Denmark confirmed the
increased risk of lung cancer among parents of HIV
patients.
We observed a twofold increased risk of lung cancer
in the HIV infected population which corresponds to
the findings of other studies that estimated standardized
incidence ratios on population based material [5,19,20].
All lung cancers are related to smoking, especially squa-
mous cell carcinoma and small cell carcinoma [21]. We
found a high prevalence of smoking among the Danish
HIV patients, where little less than 30% never smoked
compared to 40% among adults in the general back-
ground population in Denmark in the period 1987 -
2005 [22]. Accordingly, HIV patients who were smokers
Table 3 Characteristics of parents of HIV patients and population controls
Fathers of HIV
patients
Fathers of population
controls
Mothers of HIV
patients
Mothers of population
controls
N, (%) N, (%) N, (%) N, (%)
All 2,428 31,929 2,586 32,705
Median age at index date, years (IQR). 34.3 (28.6 - 41.9) 33.4 (28.3 - 40.6) 30.9 (25.8 - 37.5) 30.5 (25.7 - 36.7)
Follow-up time, median, years (IQR) 34.5 (25.2 - 40.0) 35.5 (27.6 - 40.0) 37.5 (29.0- 40.0) 38.4 (31.3 - 40.0)
Duration of follow-up, years 75,125 1,026,778 86,024 1,124,126
Emigration during follow-up, N (%) 41 (1.7) 327 (1.0) 31 (1.2) 219 (0.7)
Lost to follow-up, N (%) 4 (0.1) 13 (<0.1) 2 (0.1) 2 (<0.1)
Diagnosed with all lung cancers, (N (%)) 122 (5.0) 1233 (3.9) 78 (3.0) 763 (2.3)
Median age at diagnose of all lung cancers,
years (IQR)
65.7 (60.1 - 72.8) 65.6 (59.3 - 71.5) 60.4 (55.2 - 68.9) 64.1 (58.2 - 69.9)
Figure 3 Cumulative incidence function for lung cancer among
parents of HIV patients and parents of population controls.
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Page 7 of 10or former smokers had a considerably increased risk of
lung cancer whereas no cases of lung cancer occurred
among non-smoking HIV patients. The risk of lung can-
cer was low for women with HIV but considerably
increased for HIV infected males with heterosexual
route of infection, HIV patients with previous AIDS
defining events or low CD4 cell count in both the strati-
fied and time-update analysis. In the general population
the risk of lung cancer is lower in females correspond-
ing to our finding but the estimate was based on few
events [23]. The relative risk was considerably increased
in male patients with heterosexual route of infection
although the prevalence of smoking did not differ com-
pared to homosexually infected individuals. Guiguet et
al found an inverse correlation between risk of lung can-
cer and decreasing CD4 cell count [24]. In accordance
with this and other studies we found that immunosup-
pression predicts risk of lung cancer [8]. The mechan-
i s mb e h i n dt h i si su n k n o w nb u ta l t h o u g hp a t i e n t sw i t h
immunodeficiency at time of inclusion did not smoke
more than the rest of the HIV infected population,
immunodeficiency may accentuate the oncogenic effects
of smoking. Corresponding to the findings of other stu-
dies we found no difference in the distribution of histo-
pathological sub-types of lung cancer in the two
populations pointing towards a common set of risk fac-
tors (probably smoking) [10,11].
Also parents of HIV patients in general and in parti-
cular parents of IDUs have an excess risk of lung cancer
implying that family associated or behavioral risk factors
are involved. Smoking is related to risk-taking behaviour
which is moderately to strongly related to heritability
and offspring of smokers have a four times higher risk
of initiating smoking [25,26]. Several studies has been
conducted on this subject and concerning smoking a
social learning model of smoking initiation has been
demonstrated where adolescents imitate the behaviour
of adults over time with repeated exposure [27]. Know-
ing that the prevalence of smoking is high in the Danish
HIV patients it seems likely that smoking explains a
substantial part of the increased risk of lung cancer in
both the HIV patients and parents. HIV therefore
appears to be a marker of family related risk factors that
affect the incidence of lung cancer.
Table 4 Incidence rate ratios for lung cancer for the parent population stratified for the offspring’s route of HIV
infection
Cancer, N Unadjusted IRR (95% CI) Adjusted IRR* (95% CI)
All fathers of HIV patients** 122/1233 1.38 (1.14 - 1.66) 1.31 (1.09 - 1.58)
Stratification
Route of HIV infection for offspring
Men who have sex with men (MSM) 65/535 1.34 (1.04 - 1.73) 1.24 (0.96 - 1.61)
Heterosexually infected 31/440 1.39 (0.97 - 2.00) 1.31 (0.91 - 1.89)
Injection drug user (IDU) 20/183 1.40 (0.89 - 2.23) 1.63 (1.02 - 2.58)
All mothers of HIV infected*** 78/763 1.37 (1.08 - 1.72) 1.35 (1.07 - 1.70)
Stratification
Route of HIV infection for offspring
Men who have sex with men (MSM) 41/342 1.29 (0.93 - 1.78) 1.26 (0.90 - 1.73)
Heterosexually infected 17/262 1.20 (0.73 - 1.96) 1.20 (0.73 - 1.96)
Injection drug user (IDU) 17/112 1.84 (1.10 - 3.06) 2.01 (1.21 - 3.36)
* Adjusted for age at parent index date (continuous variable) as well as year of birth of the parent divided into the following decades: - 1920, 1920-1930, 1930-
1940, 1940-1950, 1950 - later.
** There were five cases of lung cancer among fathers of children who had other route of HIV infection and 85 among fathers of population controls.
*** There were one case of lung cancer among mothers of children who had other route of HIV infection
Figure 4 Probability of survival after diagnose of lung cancer
among HIV patients and population controls.
Engsig et al. BMC Cancer 2011, 11:272
http://www.biomedcentral.com/1471-2407/11/272
Page 8 of 10In concordance with other studies HIV patients diag-
nosed with lung cancer had an increased mortality com-
pared to the population controls [10-12]. This result
may be confounded by an increased competing risk of
death in the HIV infected population or differences in
staging of lung cancer, which we were not able to adjust
for. No difference in mortality was seen in the parent
population suggesting that the decreased survival in
HIV patients is related to HIV and not family related
risk factors.
In conclusion, the risk was especially increased in
H I Vp a t i e n t sw h ow e r es m o k e r so rf o r m e rs m o k e r s ,
heterosexually infected men or immunosuppressed.
The higher risk of lung cancer in both HIV patients
and their parents suggest that family associated risk
factors, like tobacco use, explain part of the increased
risk in HIV patients. HIV appears to be a marker of
behavioural or family related risk factors that affect the
risk of lung cancer. The use of tobacco is the major
risk factor for lung cancer and future interventions
should focus on cessation and preventing initiation of
smoking.
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definitions used in the study.
Additional file 2: Smokers or former smokers in Danish HIV
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infected.
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